公开(公告)号：EP2438926A4

公开(公告)日：2013-07-24

申请号：EP10783165

申请日：2010-06-04

申请人： NAT INST OF ADVANCED IND SCIEN ,  NAT INST INFECTIOUS DISEASES ,  M BIO TECHNOLOGY INC

发明人： MATSUDA KAZUHIRO ,  ICHIYAMA KOJI ,  MATSUDA SACHIE ,  SASAKI YUKO ,  ARAKAWA YOSHICHIKA ,  HARASAWA RYO ,  NISHIDA YOSHIHIRO ,  KATAYAMA NORIO ,  ENDO YASUO ,  NOMURA NOBUO

IPC分类号： A61K39/00 ,  A61K9/127 ,  A61K39/145 ,  A61K39/39 ,  A61K47/24 ,  A61K47/28 ,  A61P11/00 ,  A61P11/06 ,  A61P19/02 ,  A61P29/00 ,  A61P31/04 ,  A61P31/16

CPC分类号： A61K39/0241 ,  A61K9/127 ,  A61K9/1272 ,  A61K39/12 ,  A61K39/145 ,  A61K39/39 ,  A61K2039/55555 ,  A61K2039/55594

摘要： Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.

摘要翻译： 公开了对支原体感染具有高治疗效果且高度安全的疫苗。 为了开发支原体感染的有效治疗方法，提供了作为支原体感染疫苗有效的支原体模拟颗粒，并且还提供包括常见细菌的细菌模拟颗粒。 可以通过生产脂质体颗粒来提供细菌模拟颗粒，例如支原体模拟颗粒，其中作为构成脂质体的脂质组分含有诸如支原体的病原体特异性的脂质抗原。 支原体模拟颗粒的施用使得能够诱导活体中有效的免疫活性。 支原体模拟颗粒可用作预防或治疗支原体感染的优良疫苗。